Trial Profile
Safety and Effectiveness of Adalimumab (HUMIRA) in Patients Diagnosed With Rheumatoid Arthritis (DALI Study).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Nov 2011
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms DALI
- Sponsors Abbott Laboratories
- 30 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Aug 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 06 Mar 2010 New trial record